Latest news on Alzheimer's
Check out the latest news about Alzheimer's disease research that we carry out at the Barcelonaβeta Brain Research Center (BBRC). Discover the advances in Alzheimer's prevention in which our scientists participate, as well as the news of the Alfa Study, dedicated to the early detection and prevention of the disease.
Reactive astrogliosis contributes to the formation of Alzheimer’s toxic proteins and damage of brain cells in very early stages of the disease
Postdoctoral researcher Wiesje Pelkmans explains the main results of the study.
On World Alzheimer's Day we highlight the figures to forget
This September 21, we call for more research and visibility to change the social consideration of the disease through the action "4lzh31m3r: the numbers to forget"
Early action to control cardiovascular risk factors preserves brain metabolism
A study published in The Lancet Healthy Longevity shows that brain metabolism, detected with advanced imaging techniques, declines more sharply in middle-aged people with a sustained high cardiovascular risk over five years.
The BBRC participates in a study to facilitate early diagnosis of Alzheimer's with a blood test
The research center of the Pasqual Maragall Foundation has made the first visit of the EAPP study in July 2023.
Spain is among the top 10 countries in the world in Alzheimer's research
Among the most prominent research centers in Spain is the Barcelonaβeta Brain Research Center (BBRC) of the Pasqual Maragall Foundation.
Presented at AAIC the results of a new drug that would slow cognitive decline
According to the data presented, and simultaneously published in JAMA, the treatment with donanemab will significantly reduce the levels of amyloid plaque.
The BBRC participates in AAIC 2023 with eight talks and thirty posters
During the meeting, the teams will disseminate their research findings to the international scientific community.
The United States approves the commercialisation of lecanemab, a drug that could slow the progression of Alzheimer’s
In order to know the situation of the drug in Europe, it will be necessary to wait for the resolution of the European Medicines Agency.
"More resources for better research": the 2022 Report of the Pasqual Maragall Foundation and the BBRC is now available
The document collects the most outstanding annual information on the scientific, social and economic activity of the two entities.
